Visus Therapeutics to Present at 2023 JMP Securities Life Science Conference

Company Announced Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia.

BRIMOCHOL™ PF met its prespecified FDA primary endpoint for binocular near visual acuity across multiple time points, starting at hour 1, versus active controls, and was well-tolerated with no significant adverse events.

Non-surgical drug candidate to reverse cataracts expected to advance into clinical development in 2023.

SEATTLE & IRVINE, Calif--(BUSINESS WIRE)--Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today announced that Ben Bergo, co-founder, and chief executive officer, will present at the JMP Securities Life Science Conference on May 15th, 2023, at the New York Hilton Midtown.

The presentation is scheduled for 10:00 AM Eastern Time on Monday, May 15^th. A live webcast of the presentation will be available at: https://bit.ly/JMPwebcast.

Mr. Bergo will also be available for one-on-one meetings with investors on May 15^th and May 16^th.

About Visus Therapeutics

With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. Visit: visustx.com and follow us on LinkedIn, Twitter, and Instagram.